RWE Supporting CDK4/6 Inhibitor Use in HR+ Metastatic Breast Cancer
Christopher M. Gallagher, MD
Real World Use of RWE in HR+ Metastatic Breast Cancer: The Oncologist Perspective
Adam Brufsky, MD, PhD
Balancing the Scales: The Complementary Roles of RCTs and RWE in Modern Healthcare
RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer
Distinguishing Between High- and Low-Quality RWE: A Journal Club for the Real World
Unlocking Insights for Underrepresented Patients: The Role of Real-World Evidence in Addressing Limitations of CDK4/6 Inhibitor RCTs
Real World Evidence To Expand Knowledge of CDK4/6 Inhibitor-Related Adverse Effects
Importance of the Patient Perspective on RWE in Formulating SDM Conversations
Early Breast Cancer Care: Omitting Radiation Therapy Linked to Less Fear of Recurrence
Staying Up to Date on Advancements in Triple-Negative Breast Cancer Care
Case Study: Sequencing Therapy in ES-SCLC in Special Patient Populations
Ticiana Leal, MD
Jacob Sands, MD
Case: Adjuvant Immunotherapy in Localized NSCLC
Joshua E. Reuss, MD
Jessica S. Donington, MD, MSCR
Case: Update of Neoadjuvant Therapies for Resectable Lung Cancer
Case Study: Managing Common Adverse Events Associated with Second-Line Treatment of ES-SCLC
Case Study: Treatment Sequencing in Platinum-Resistant Relapse ES-SCLC
Case Study: Treatment Sequencing in Platinum-Sensitive Relapse ES-SCLC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.